Free Trial

Dr. Reddy's Laboratories (RDY) Stock Forecast & Price Target

$78.54
+0.19 (+0.24%)
(As of 09/20/2024 ET)

Dr. Reddy's Laboratories - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 2 Wall Street analysts who have issued ratings for Dr. Reddy's Laboratories in the last 12 months, the stock has a consensus rating of "Hold." Out of the 2 analysts, 1 has given a sell rating, and 1 has given a buy rating for RDY.

Consensus Price Target

$87.00
10.77% Upside
High Forecast$87.00
Average Forecast$87.00
Low Forecast$87.00

According to the 2 analysts' twelve-month price targets for Dr. Reddy's Laboratories, the average price target is $87.00. The highest price target for RDY is $87.00, while the lowest price target for RDY is $87.00. The average price target represents a forecasted upside of 10.77% from the current price of $78.54.

TypeCurrent Forecast
9/22/23 to 9/21/24
1 Month Ago
8/23/23 to 8/22/24
3 Months Ago
6/24/23 to 6/23/24
1 Year Ago
9/22/22 to 9/22/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$87.00$87.00$81.00$70.00
Forecasted Upside10.77% Upside6.06% Upside13.49% Upside26.74% Upside
Get Dr. Reddy's Laboratories Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.

RDY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RDY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Dr. Reddy's Laboratories Stock vs. The Competition

TypeDr. Reddy's LaboratoriesMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.78
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside10.77% Upside876.70% Upside7.41% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/30/2024Barclays
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$81.00 ➝ $87.00+6.06%
1/11/2024Jefferies Financial Group
2 of 5 stars
 DowngradeBuy ➝ Underperform
8/29/2023HSBC
2 of 5 stars
 DowngradeBuy ➝ Hold
5/18/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
3/17/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
1/30/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageUnderweight
11/14/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:40 AM ET.

RDY Forecast - Frequently Asked Questions

What is Dr. Reddy's Laboratories' forecast for 2024?

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Dr. Reddy's Laboratories is $87.00, with a high forecast of $87.00 and a low forecast of $87.00.

Should I buy or sell Dr. Reddy's Laboratories stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last year. There is currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RDY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDY, but not buy additional shares or sell existing shares.

Does Dr. Reddy's Laboratories's stock price have much upside?

According to analysts, Dr. Reddy's Laboratories's stock has a predicted upside of 6.06% based on their 12-month stock forecasts.

What analysts cover Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories has been rated by research analysts at Barclays in the past 90 days.

Do Wall Street analysts like Dr. Reddy's Laboratories more than its competitors?

Analysts like Dr. Reddy's Laboratories less than other "medical" companies. The consensus rating for Dr. Reddy's Laboratories is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RDY compares to other companies.



This page (NYSE:RDY) was last updated on 9/21/2024 by MarketBeat.com Staff
From Our Partners